PCDHGB7 alone has a sensitivity of 100.0% and a specificity of 88.7% for cervical cancer (Figure 4B), and an 82.1% sensitivity and 88.7% specificity for HSIL+ samples30. Here, PCDHGB7 is linked to cervical carcinoma.